Sign in
LUMO Stock Price, Chart, Stats & News
Lumos Pharma, Inc.
Save
37.54M
Market cap
–
Current P/E
–
Forward P/E
LUMO chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 100.00% |
Operating margin | -1785.18% |
Pretax margin | -1660.80% |
Net margin | -1659.39% |
Effective tax rate | 0.09% |
ROA | -83.75% |
ROE | -78.34% |
D/E | 0.02x |
Interest coverage ratio | – |
LUMO valuation
P/E | – |
P/S | 18.30x |
P/B | 1.29x |
P/CF | -1.14x |
P/FCF | -1.21x |
P/OCF | -1.14x |
PEG | -0.33x |
EV multiple | -1.97x |
About
Lumos Pharma, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to advancing and commercializing medical treatments for rare conditions. Their principal therapeutic compound, LUM-201, an orally administered growth hormone secretagogue called ibutamoren, is currently undergoing Phase 2 clinical evaluation. This drug candidate is being investigated for its potential in treating pediatric growth hormone deficiency and various other uncommon endocrine conditions.
Similar securities
Based on sector and market capitalization
Report issue